Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Forigerimod - ImmuPharma

Next Previous
Drug Profile

Forigerimod - ImmuPharma

Alternative Names: CEP-33457; IPP-201101; Lupuzor; peptide P140; Rigerimod; SyB 1001

Latest Information Update: 03 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CNRS
  • Developer ImmuPharma
  • Class Oligopeptides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Systemic lupus erythematosus
  • Phase II Chronic inflammatory demyelinating polyradiculoneuropathy
  • Preclinical Asthma; Gout; Periodontitis

Most Recent Events

  • 03 Dec 2024 Forigerimod is still in phase-III trial for Systemic lupus erythematosus in Puerto Rico, Italy and Mauritus (SC)
  • 21 Mar 2023 ImmuPharma completes a phase I pharmacokinetics trial (In volunteers) in Whales and United Kingdom (IV, SC) (ISRCTN16878305)
  • 28 Nov 2022 Phase-II clinical trials in Chronic inflammatory demyelinating polyradiculoneuropathy (SC) (ImmuPharma pipeline, November 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top